MSLN and familial pancreatic carcinoma: In a recent pre-clinical trial, a novel replication-defective recombinant adenovirus 40 (rAd40) expressing mouse mesothelin (Msln) was administrated intravenously in mouse models as a prophylactic cancer vaccine against metastatic lesions of pancreatic cancer.